Clinical trials in ovarian carcinoma: Requirements for standard approaches and regimens

Annals of Oncology

Volumn 16, Issue SUPPL. 8, 2005, Pages

  Thigpen, T ^a,b   Stuart, G ^a   du Bois, A ^a   Friedlander, M ^a   Fujiwara, K ^a   Guastalla, J P ^a   Kaye, S ^a   Kitchener, H ^a   Kristensen, G ^a   Mannel, R ^a   Meier, W ^a   Miller, B ^a   Poveda, A ^a   Provencher, D ^a   Stehman, F ^a   Vergote, I ^a  

^a GOG ^*  (New Zealand)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; MELPHALAN; PACLITAXEL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; TOPOTECAN;

AREA UNDER THE CURVE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; CYTOREDUCTIVE SURGERY; DISEASE SEVERITY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG CONTRAINDICATION; DRUG EFFICACY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; META ANALYSIS; OVARIECTOMY; OVARY CARCINOMA; POPULATION RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; SIDE EFFECT; VALIDATION PROCESS;

CLINICAL TRIALS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; OVARIAN NEOPLASMS;

EID: 27744580699     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdi962     Document Type: Conference Paper

References (35)

1. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6.
2. Muggia FM, Braly PS, Brady MF et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 2000; 18: 106-115.
3. The International Collaborative Ovarian Neoplasm (ICON) Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomised trial. Lancet 2002; 360: 505-515.
4. Piccart MJ, Bertelsen K, James K et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results. J Natl Cancer Inst 2000; 92: 699-708.
5. van der Burg MEL, van Lent M, Buyse M et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 1995; 332: 629.
6. Rose P, Nerenstone S, Brady M et al. A phase III randomized study of interval secondary cytoreduction in patients with advanced stage ovarian carcinoma with suboptimal residual disease: A Gynecologic Oncology Group study. Proc Am Soc Clin Oncol 2002; 21: 201a (Abstr).
7. Tyler CW, Lee NC, Robboy SJ et al. The diagnosis of ovarian cancer by pathologists: How often do diagnoses by contributing pathologists agree with a panel of gynecologic pathologists? Am J Obstet Gynecol 1991; 164: 65-70.
8. Baak JPA, Langley FA, Talerman A et al. Interpathologist and intrapathologist disagreement in ovarian tumor grading and typing. Anal Quant Cytol Histol 1986; 8: 354-357.
9. Cramer SF, Roth LM, Ulbright TM et al. Evaluation of the reproducibility of the World Health Organization classification of common ovarian cancers with emphasis on methodology. Arch Pathol Lab Med 1987; 111: 819-829.
10. The new FIGO stage grouping for primary carcinoma of the ovary (1985). Gynecol Oncol 1986; 25: 383.
11. Hoskins W, Bundy B, Thigpen T, Omura G. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: A Gynecologic Oncology Group study. Gynecol Oncol 1992; 47: 159-166.
12. Hoskins WJ, McGuire WP, Brady MF et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994; 170: 974-980.
13. Allen DG, Heintz AP, Touw FW. A meta-analysis of residual disease and survival in stage III and IV carcinoma of the ovary. Eur J Gynaecol Oncol 1995; 16: 349-356.
14. Bristow RE, Tomacruz RS, Armstrong DK et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum-era: A meta-analysis. J Clin Oncol 2002; 20: 1248-1259.
15. Covens AL. A critique of surgical cytoreduction in advanced ovarian cancer. Gynecol Oncol 2000; 78: 269-274.
16. Tingulstad S, Skjedestad F, Hagen B. The effect of centralization of primary surgery on survival in ovarian cancer patients. Obstet Gynecol 2003; 102: 499-505.
17. Nguyen H, Averette H, Hoskins W et al. National survey of ovarian carcinoma. Part V. The impact of physician's specialty on patients' survival. Cancer 1993; 72: 3663-3670.
18. Eisenkopf S, Spirtos N, Montag T et al. The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol Oncol 1992; 47: 203 209.
19. Kehoe S, Powell J, Wilson S, Woodman C. The influence of the operating surgeon's specialization on patient survival in ovarian carcinoma. Br J Cancer 1994; 70: 1014-1017.
20. Junor E, Hole D, McNulty L et al. Specialist gynaecologists and survival outcome in ovarian cancer: A Scottish national study of 1866 patients. Br J Obstet Gynaecol 1999; 106: 1130-1136.
21. Favalli G, Odinico F, Pecorelli S. Surgery of advanced malignant epithelial tumours of the ovary. Forum (Genova) 2000; 10: 312-320.
22. Dauplat J, Le Bouedec G, Pomel C, Scherer C. Cytoreductive surgery for advanced stages of ovarian cancer. Semin Surg Oncol 2000; 19: 42-48.
23. ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4/AGO-OVAR-2.2 trial. Lancet 2003; 361: 2099-2106.
24. Gordon A, Fleagle J, Guthrie D et al. Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19: 3312-3322.
25. Pfisterer J, Plante M, Vergote I et al. Gemcitabine/carboplatin vs carboplatin in platinum sensitive recurrent ovarian cancer. Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG. Proc Am Soc Clin Oncol 2004; 23: 449 (Abstr 5005).
26. du Bois A, Luck H-J, Meier W et al. A randomized clinical trial of cispaltin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003; 95: 1320-1330.
27. Ozols R, Bundy B, Greer B et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 2003; 21: 3194-3200.
28. Rowinsky E, Mackey M, Goodman S. Meta-analysis of paclitaxel dose response and dose intensity in recurrent or refractory ovarian cancer. Proc Am Soc Clin Oncol 1996; 15: 284.
29. Eisenhauer E, ten Bokkel Huinink W, Swenerton K et al. European Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol 1994; 12: 2654-2666.
30. Omura G, Brady M, Delmore J et al. A randomized trial of paclitaxel at 2 dose levels and filgastrim at 2 dose levels in platinum pretreated epithelial ovarian cancer: A GOG, SWOG, NCCTTG, and ECOG study. Proc Am Soc Clin Oncol 1996; 15: 280.
31. Pertussini E, Ratajczak J, Majka M et al. Investigating the plateletsparing mechanism of paclitaxel/carboplatin combination chemotherapy. Blood 2001; 97: 638-644.
32. Bertelsen K, Jakobsen A, Stroyer J et al. A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: A Danish Ovarian Study Group trial (DACOVA). Gynecol Oncol 1993; 49: 30-36.
33. Hakes TB, Chalas E, Hoskins WJ et al. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecol Oncol 1992; 45: 284-289.
34. Bolis G, Colombo N, Favalli G et al. Randomized multicenter clinical trials in stage I epithelial ovarian cancer. Proc Am Soc Clin Oncol 1992; 11: 225.
35. ICON and ACTION Collaborators. International collaborative ovarian neoplasm trial I and adjuvant chemotherapy in ovarian neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 2003; 95: 105-112.